Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Remon, J., Soria, J. C., Peters, S. & ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann. Oncol. 32, 1637–1642 (2021).

Article  CAS  PubMed  Google Scholar 

Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 (2008).

Article  PubMed  Google Scholar 

Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. Lancet 398, 535–554 (2021).

Article  PubMed  Google Scholar 

Saw, S. P. L., Ong, B. H., Chua, K. L. M., Takano, A. & Tan, D. S. W. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol. 22, e501–e516 (2021).

Article  CAS  PubMed  Google Scholar 

Cascone, T. et al. Perioperative nivolumab in resectable lung cancer. N. Engl. J. Med. 390, 1756–1769 (2024).

Article  CAS  PubMed  Google Scholar 

Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750–768 (2022).

Article  CAS  PubMed  Google Scholar 

Mosele, F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 31, 1491–1505 (2020).

Article  CAS  PubMed  Google Scholar 

Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339–357 (2023).

Article  CAS  PubMed  Google Scholar 

Mack, P. C. et al. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: analysis of over 8000 cases. Cancer 126, 3219–3228 (2020).

Article  CAS  PubMed  Google Scholar 

Roma, C. et al. Low impact of clonal hematopoiesis on the determination of RAS mutations by cell-free DNA testing in routine clinical diagnostics. Diagnostics 12, 1956 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggarwal, C. et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 5, 173–180 (2019).

Article  PubMed  Google Scholar 

Pasquale, R. et al. Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. Transl. Lung Cancer Res. 9, 61–70 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leighl, N. B. et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 4691–4700 (2019).

Article  CAS  PubMed  Google Scholar 

Schwaederle, M. C. et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin. Cancer Res. 23, 5101–5111 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Remon, J. et al. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE 15, e0234302 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papadopoulou, E. et al. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS ONE 14, e0226853 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo, A. et al. Liquid biopsy of lung cancer before pathological diagnosis is associated with shorter time to treatment. JCO Precis. Oncol. 8, e2300535 (2024).

Article  PubMed  Google Scholar 

Normanno, N. et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann. Oncol. 29, 112–118 (2018).

Article  CAS  PubMed  Google Scholar 

Bestvina, C. M. et al. Early-stage lung cancer: using circulating tumor DNA to get personal. J. Clin. Oncol. 41, 4093–4096 (2023).

Article  CAS  PubMed  Google Scholar 

Nagasaka, M. et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol. Cancer 20, 82 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259–268 (2023).

Article  CAS  PubMed  Google Scholar 

Normanno, N., Cervantes, A., Ciardiello, F., De Luca, A. & Pinto, C. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev. 70, 1–8 (2018).

Article  CAS  PubMed  Google Scholar 

Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297–312 (2021).

Article  PubMed  Google Scholar 

Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).

Article  CAS  PubMed  Google Scholar 

Dasari, A. et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol. 17, 757–770 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Pantel, K. & Alix-Panabieres, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409–424 (2019).

Article  CAS  PubMed  Google Scholar 

Pellini, B. & Chaudhuri, A. A. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J. Clin. Oncol. 40, 567–575 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moding, E. J., Nabet, B. Y., Alizadeh, A. A. & Diehn, M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 11, 2968–2986 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anagnostou, V. & Velculescu, V. E. Pushing the boundaries of liquid biopsies for early precision intervention. Cancer Discov. 14, 615–619 (2024).

Article  CAS  PubMed  Google Scholar 

Esposito Abate, R. et al. Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls. Cancers 12, 3804 (2020).

Article  PubMed  PubMed Central